Nominations open for GSK Award for Research Excellence

Nominations for GSK’s Award for Research Excellence are open until 6 July 2018. The longstanding award seeks to assist leading Australian researchers by providing the winner with an $80,000 grant to support their research journey.

The GSK Award for Research Excellence is one of the most prestigious available to the Australian medical research community. It has been awarded since 1980 to recognise outstanding achievements in medical research with potential importance to human health.

Last year’s award was received by Professor Timothy Hughes – considered a world-leader in chronic myeloid leukaemia (CML) research – for pioneering the use of tyrosine kinase inhibitors (TKIs) in the treatment of CML. You can view his winning video here.

Speaking about the award, Professor Hughes said “Awards like GSK’s Award for Research Excellence bring much needed support to the research community in Australia. Not only through the direct impact of the award’s funding, but also through raising awareness of the scientific expertise and innovative activities in our country.”

Professor Hughes and his team at the South Australian Health and Medical Research Institute are currently focused on treatment response to optimise disease management and patient outcomes. The $80,000 prize that comes with the GSK Award for Research Excellence will help support a Leukaemia Fellow to work alongside Professor Hughes in furthering research into CML.

The award was presented to Professor Hughes at Research Australia’s Health and Medical Research Awards 2017 in Melbourne. Dr Andrew Weekes, Medical Director, GSK Australia, said, “GSK is proud to be able to support Australian researchers with this award, now in its 38th year.

Successful applicants are generally mid-career researchers with a long-standing commitment to their field. The winner will be announced on Thursday 8 November 2018 at the Research Australia Health and Medical Research Awards dinner, being held at the Sofitel Sydney, Darling Harbour.

Further information is available on the GSK ARE website where nominees may be submitted. Please email any enquires to are.arenominations@gsk.com. Nominations close 2 July 2018.

 

Research for a Sustainable WA Health System

Research Australia has urged the Expert Panel responsible for undertaking WA’s Sustainable Health Review to give greater emphasis to the role health and medical research can play in creating a more sustainable health system for Western Australians.

While welcoming the identification by the Review Panel of the need to ‘Harness and support health and medical research, collaboration and innovation’ as one of the Interim Report’s 12 Directions, our response further elaborates the role for health and medical research in achieving the other 11 Directions identified by the Review Panel. We have used examples and case studies provided by our WA members to highlight the many ways that research is already helping reform WA’s health system, and the many opportunities to further leverage and expand this partnership for the benefit of the whole community.

Research Australia’s submission to the WA Sustainable Health Review

Federal Budget 2018/19 – Have Your Say

The Assistant Treasurer has called for ideas for next year’s Federal Budget to be submitted by 15 December 2017.

Research Australia is working on its submission and is looking for suggestions from our membership.

Have an idea for something that should be funded by the Commonwealth Government but isn’t?

An area that deserves more funding than it currently gets?

Research Australia wants to hear from you.

Please send your ideas to Greg Mullins or call Greg on 03 9662 9420.

As an example, here is a link to Research Australia’s 2016 pre-budget submission.

Medical technology investment to improve lives

11 September 2017

The Biomedical Translation Fund will fund three medical breakthroughs, as announced jointly by The Hon Greg Hunt MP, Health and Sports Minister and Senator The Hon Arthur Sinodinos, Minister for Industry, Innovation ad Science.

The investments are being made for the BTF by one of its three fund managers, BioScience Managers:

  • $5 million in Rex Bionics to develop a hands-free robotic device to help people with severe
    disability to walk, exercise and rehabilitate;
  • $3.3 million to Saluda Medical for neuromodulation technologies for people suffering from
    chronic back pain and other debilitating conditions;
  • $5 million to CHARM Informatics for data aggregation and commercialisation services for
    makers of ‘smart’ medical devices.

A joint venture between the Australian Government and private sector investors, further investments are yet to be made, with a total of $500 million available.

Read the full media release about the Biomedical Translation Fund.

Continue reading “Medical technology investment to improve lives”

The Australian Health Data Series

Flying Blind | The Australian Health Data Series 

Flying Blind is a series of three reports dedicated to uncovering the acute levels of data fragmentation existing at all levels of Australia’s health landscape.

CMCRC in collaboration with Research Australia is currently working on the second report which examines Australia’s health and medical research data environment and traces the difficulties that Australian researchers face at each stage of their journey as they attempt to access research data. Volume One dived into consumers and digital health through the patient journey, service fragmentation, health data silos, legislation, regulation and policy and consumer concerns and perceptions.

As we write Volume Two: Researchers and the Health Data Maze, we’ll be publishing regular blog posts of interest to this topic. The blog is updated regularly by members of the CMCRC’s Health Market Quality program and Research Australia. If you would like to be a guest blogger please email Lucy Clynes with your expressions of interest.

Bookmark this website today: https://flyingblind.cmcrc.com/researchers-health-data.
Continue reading “The Australian Health Data Series”

Temporary Work (Skilled) visa subclass 457 scrapped

This week, the Prime Minister announced that the Temporary Work (Skilled) visa (subclass 457 visa) will be abolished and replaced with the completely new Temporary Skill Shortage (TSS) visa in March 2018.

The TSS visa program will be comprised of a Short-Term stream of up to two years and a Medium-Term stream of up to four years and will support businesses ‘in addressing genuine skill shortages in their workforce and will contain a number of safeguards which prioritise Australian workers.’
Continue reading “Temporary Work (Skilled) visa subclass 457 scrapped”

Research & Development Tax Incentive

Joint statement on the Research & Development Tax Incentive

Don’t rip the guts out of Australian medical research commercialisation

Commercialisation of Australian medical research is under serious threat if the package of measures put by the ‘Ferris, Finkel, Fraser’ Review of the Research & Development (R&D) Tax Incentive is adopted and Australia’s medical technology, biotechnology, and pharmaceutical (MTP) sector is urging the Federal Government not to devastate Australia’s most innovative industry.

The R&D Tax Incentive is the most critical centre-piece program in the translation of Australia’s world-class research into treatments, cures, diagnostics, medical devices and vaccines. The program has been successful in helping attract more investment in R&D and fostering a strong Australian life sciences clinical trials and R&D sector.
Continue reading “Research & Development Tax Incentive”

Health and medical researchers welcome appointment of Hon Brad Hazzard MP to Health portfolio

30 January 2017

Australia’s peak body for health and medical research has welcomed the appointment of the
Hon Brad Hazzard MP as Minister for Health and Minister for Medical Research.

“Bringing health and medical research back under one senior minister presents new opportunities to better integrate health and medical research with clinical care. This will mean better outcomes for patients and opportunities to achieve sustainable spending within the NSW health budget,” Research Australia CEO Nadia Levin said. Continue reading “Health and medical researchers welcome appointment of Hon Brad Hazzard MP to Health portfolio”

INSPIRE Magazine

Summer 2016 Issue Out Now!

We are delighted to share with you the Summer Issue of Research Australia’s quarterly publication – INSPIRE.

It is has been such a busy year in the health and medical research industry and what a better way to celebrate the contribution our Members have had than through Research Australia’s annual Awards; GSK Award for Research Excellence; Bupa Health Foundation Emerging Health Researcher Award and Sax Institute’s annual Research Action Awards. Enjoy reading about the recipients of these awards and lives they are changing. Continue reading “INSPIRE Magazine”

2015 Peter Wills Medal: Prof Sharon Lewin

Research Australia
Health & Medical Research Awards

2015 Peter Wills Medal

The Peter Wills Medal was created in 2011 to mark research Australia’s 10th anniversary. It recognises an Australian who has made an outstanding contribution to building Australia’s international reputation in the area of health & medical research, and for harnessing government, research, industry and philanthropic collaborations to promote better health

Award Winner

Professor Sharon Lewin
Inaugural Director
Peter Doherty Institute For Infection & Immunity

Sharon Lewin is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital; Professor of Medicine, The University of Melbourne; consultant infectious diseases physician, Alfred Hospital, Melbourne, Australia; and an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellow. She is an infectious diseases physician and basic scientist.

Sharon completed her medical training (MB., BS (Hons) 1986) and her PhD (1996) in Microbiology at Monash University, Melbourne Australia. She was trained in clinical infectious diseases in Melbourne (FRACP 1996) and did her post-doctoral fellowship with Professor David Ho at the Aaron Diamond Research Centre at the Rockefeller University, New York (1997-1999). David Ho was named Time Man of the Year in 1996 for his major contribution to discovering successful antiviral therapy for HIV. She was Director, Department of Infectious Diseases, Alfred Hospital and Monash University (2003-2014) and co-head of the Centre for Biomedical Research at the Burnet Institute (2011-2014), Melbourne, Australia.

She leads a large multi-disciplinary research team that focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. Her other research and clinical interests include understanding how the immune system recovers following treatment of HIV and the interaction between HIV and other important co-infections including hepatitis B virus. She is widely recognized for her innovative work in understanding how HIV hides on treatment using novel laboratory models and leading several early phase clinical trials of cancer drugs that alter HIV genes. Her clinical trial program is part of a close collaboration with the Department of Infectious Diseases, Alfred Hospital and Monash University.

She has published over 200 publications and her laboratory receives funding from the NHMRC, the National Institutes for Health (NIH), the Wellcome Trust and the American Foundation for AIDS Research. She has extensive collaborations in Asia including Thailand, Malaysia, China and India as well as collaborations with investigators throughout the US and Europe. She is a co-principal investigator for the Delaney AIDS Research Enterprise to find a Cure – a $25million NIH funded program grant of over 30 investigators working on immunological interventions to develop a cure for HIV.

She was the local co-chair of the XXth International AIDS Conference (AIDS2014) which was held in Melbourne July 2015, which attracted over 14,000 participants and was the largest health conference ever held in Australia. In 2015, she became a member of the council of the NHMRC and chairs the newly established NHMRC Health Translation Advisory Committee.

In 2014 she was named Melburnian of the Year. This is an award made each year by the City of Melbourne to an inspirational role model who has made an outstanding contribution to the city in their chosen field. This was the first time the award was made to a physician or scientist.

Sharon is married to Bob Milstein, a health lawyer. They have two adult sons, Alex and Max who are mad Essendon supporters. She is a passionate Melburnian!

Prof Lewin & Peter Wills
Prof Lewin & Peter Wills